Sublingual vs Oral Immunotherapy for Peanut Allergy

Neither is simply better; they trade efficacy against safety. Oral immunotherapy, including the FDA-approved product Palforzia, has stronger evidence that it can raise the amount of peanut a person tolerates, which may reduce the danger of accidental exposure, but it causes allergic reactions more frequently and requires close supervision. Sublingual peanut immunotherapy tends to be milder, with mostly local side effects, but produces smaller tolerance gains and rests on more limited evidence. The right choice depends on the individual's goals, reaction history and tolerance for risk, and it should be made with an allergist. Neither approach cures peanut allergy outright.

Palforzia is an FDA-approved oral immunotherapy product for peanut allergy, made of standardized peanut protein given in carefully measured, escalating doses to eligible children. It represents the regulated, standardized form of peanut OIT and is the reason oral immunotherapy has a stronger evidence and approval footing for peanut than sublingual approaches do. Like other OIT, it aims to raise the tolerated dose rather than cure the allergy, and allergic reactions during treatment are common, so it is administered under medical supervision. Sublingual peanut immunotherapy has no comparable FDA-approved product and remains less established. Eligibility and suitability are determined by an allergist.

Peanut oral immunotherapy has been studied in larger randomized trials, including the studies supporting Palforzia, which built a more robust evidence base and led to FDA approval. Sublingual peanut immunotherapy has been examined in smaller studies that suggest modest desensitization with milder side effects, but the trials are fewer and the tolerance gains generally smaller, so confidence in the results is lower. Food SLIT in general is considered especially off-label, and conclusions should be hedged accordingly. This does not mean SLIT is ineffective, only that its evidence is less mature, which is why treatment decisions should be individualized with an allergist.

Allergic reactions tend to be more common and sometimes more systemic with peanut oral immunotherapy, because the route involves swallowing increasing amounts of peanut protein, which can provoke the immune system more strongly. Sublingual peanut immunotherapy generally causes milder, more local reactions such as itching of the mouth or throat. This is why OIT dose escalations are supervised closely and an epinephrine auto-injector is required. The greater reaction frequency of OIT is part of the trade-off for its larger tolerance gains. No food immunotherapy is risk-free, and both require careful management by a specialist familiar with food allergy.

No. Neither oral nor sublingual peanut immunotherapy is a guaranteed cure. The goal of these treatments is desensitization, meaning raising the amount of peanut a person can tolerate so that an accidental exposure is less likely to cause a severe reaction. This protective effect often depends on continued dosing and can diminish if treatment stops. Results vary widely between individuals, and the therapies modify the allergic response rather than permanently eliminating the allergy. Because peanut reactions can be severe, any immunotherapy should be undertaken only under the guidance of an allergist who can weigh the benefits and risks for that person.